arrow_back Back to App

Drug Discount Access: Protecting the 340B Program

This bill aims to ensure that hospitals and clinics can continue to purchase medications at discounted prices, regardless of where or how they are dispensed to patients. This program allows healthcare facilities to save money, which they then use to provide more comprehensive health services to their communities, directly translating into better access to care for citizens.
Key points
Drug manufacturers must offer discounted drug prices, regardless of whether the drugs are dispensed directly by the facility or through contract pharmacies.
The bill prohibits drug manufacturers from imposing conditions that would hinder healthcare facilities from purchasing discounted drugs or dispensing them to patients.
It introduces financial penalties for drug manufacturers who violate the discount program rules, aiming to protect drug accessibility for patients.
It allows healthcare facilities to report violations by drug manufacturers, increasing their protection and ensuring compliance with program rules.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_2372
Sponsor: Sen. Welch, Peter [D-VT]
Process start date: 2025-07-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

340B PATIENTS Act of 2025

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_2372.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-07-22.

What are the main provisions?

Key points include:

  • Drug manufacturers must offer discounted drug prices, regardless of whether the drugs are dispensed directly by the facility or through contract pharmacies.
  • The bill prohibits drug manufacturers from imposing conditions that would hinder healthcare facilities from purchasing discounted drugs or dispensing them to patients.
  • It introduces financial penalties for drug manufacturers who violate the discount program rules, aiming to protect drug accessibility for patients.
  • It allows healthcare facilities to report violations by drug manufacturers, increasing their protection and ensuring compliance with program rules.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Welch, Peter [D-VT].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health